Cargando…

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia

OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil, Fabio, Juliao-Baños, Fabian, Amador, Luisa, Castano, Natalia, Reyes, Juan Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596638/
https://www.ncbi.nlm.nih.gov/pubmed/35943702
http://dx.doi.org/10.1007/s41669-022-00360-4
_version_ 1784815914251714560
author Gil, Fabio
Juliao-Baños, Fabian
Amador, Luisa
Castano, Natalia
Reyes, Juan Manuel
author_facet Gil, Fabio
Juliao-Baños, Fabian
Amador, Luisa
Castano, Natalia
Reyes, Juan Manuel
author_sort Gil, Fabio
collection PubMed
description OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). METHODS: A Markov model was constructed with 8-week cycles, simulating a cohort of patients in a 5-year time horizon. The health states included remission, treatment response, active UC, and colectomy. The transition probabilities for the induction and maintenance phase were obtained from a network meta-analysis, and effectiveness was measured using quality-adjusted life-years (QALYs). Unit costs were derived from official national sources. RESULTS: For first line, the incremental cost-effectiveness ratio (ICER) per QALY was $883 for tofacitinib and $3619 for infliximab, compared with adalimumab. Sensitivity analysis showed that tofacitinib is cost effective in 45% of the iterations, adalimumab in 5%, and infliximab in 50%. Meanwhile, the ICER of adalimumab was $14,927 compared with tofacitinib in second-line treatment. In the sensitivity analysis, tofacitinib was cost effective in 64% of the iterations, followed by adalimumab in 36%. Infliximab and golimumab were not included due to data limitations in the network meta-analysis of second-line treatment. CONCLUSION: The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00360-4.
format Online
Article
Text
id pubmed-9596638
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95966382022-10-27 Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia Gil, Fabio Juliao-Baños, Fabian Amador, Luisa Castano, Natalia Reyes, Juan Manuel Pharmacoecon Open Original Research Article OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). METHODS: A Markov model was constructed with 8-week cycles, simulating a cohort of patients in a 5-year time horizon. The health states included remission, treatment response, active UC, and colectomy. The transition probabilities for the induction and maintenance phase were obtained from a network meta-analysis, and effectiveness was measured using quality-adjusted life-years (QALYs). Unit costs were derived from official national sources. RESULTS: For first line, the incremental cost-effectiveness ratio (ICER) per QALY was $883 for tofacitinib and $3619 for infliximab, compared with adalimumab. Sensitivity analysis showed that tofacitinib is cost effective in 45% of the iterations, adalimumab in 5%, and infliximab in 50%. Meanwhile, the ICER of adalimumab was $14,927 compared with tofacitinib in second-line treatment. In the sensitivity analysis, tofacitinib was cost effective in 64% of the iterations, followed by adalimumab in 36%. Infliximab and golimumab were not included due to data limitations in the network meta-analysis of second-line treatment. CONCLUSION: The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00360-4. Springer International Publishing 2022-08-09 /pmc/articles/PMC9596638/ /pubmed/35943702 http://dx.doi.org/10.1007/s41669-022-00360-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Gil, Fabio
Juliao-Baños, Fabian
Amador, Luisa
Castano, Natalia
Reyes, Juan Manuel
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
title Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
title_full Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
title_fullStr Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
title_full_unstemmed Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
title_short Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
title_sort cost effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in colombia
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596638/
https://www.ncbi.nlm.nih.gov/pubmed/35943702
http://dx.doi.org/10.1007/s41669-022-00360-4
work_keys_str_mv AT gilfabio costeffectivenessoftofacitinibforthetreatmentofmoderatetosevereactiveulcerativecolitisincolombia
AT juliaobanosfabian costeffectivenessoftofacitinibforthetreatmentofmoderatetosevereactiveulcerativecolitisincolombia
AT amadorluisa costeffectivenessoftofacitinibforthetreatmentofmoderatetosevereactiveulcerativecolitisincolombia
AT castanonatalia costeffectivenessoftofacitinibforthetreatmentofmoderatetosevereactiveulcerativecolitisincolombia
AT reyesjuanmanuel costeffectivenessoftofacitinibforthetreatmentofmoderatetosevereactiveulcerativecolitisincolombia